Cellipont Bioservices, a company that specializes in cell therapy manufacturing, has teamed up with Soter Bio, a company that focuses on RNA and RNA-lipid nanoparticle manufacturing. Together, they will help create a more efficient manufacturing process for complex cell therapy programs that require both biomolecule and cell processing.
Under this partnership, Cellipont will handle the manufacturing of cell therapies, as well as the necessary testing and regulatory work, from early clinical trials to later stages. Soter Bio will provide RNA and biomolecule manufacturing to support the cell engineering process for advanced treatments.
This collaboration aims to speed up development, reduce technical handoffs, and strengthen U.S. manufacturing for advanced therapies. The goal is to offer a complete, U.S.-based solution for RNA production and cell processing. This reflects a growing trend in the industry toward integrated manufacturing systems for RNA and cell therapies.
The partnership will support a variety of programs, including cell therapies in research and those backed by government and biotech companies. Both Cellipont and Soter Bio will continue to operate independently but will work together to serve their clients.
Executive Statement
According to Darren Head, CEO at Cellipont, as cell therapies and RNA-enabled approaches become more technically integrated, early alignment across manufacturing stages is critical to de-risk development and move programs efficiently into the clinic. Their collaboration with Soter Bio strengthens the domestic manufacturing pathway and provides sponsors with a coordinated model from RNA and biomolecule supply through GMP cell therapy production.
According to Mike Stewart, Founder and CEO of Soter Bio, soter Bio was built to support advanced therapeutic programs that depend on reliable, rapid, scalable input materials. Partnering with Cellipont brings complementary GMP expertise to help sponsors navigate complex development programs while maintaining regulatory rigor and supply continuity.